Adrenocortical Mitochondria-Associated Membranes: Isolation, Characterization, and Lipidoproteomic Response to

Alexander F Krüger1, Werner Schmitz2, Stephanie Lamer3

  • 1Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, 97080 Würzburg, Germany.

PubMed

Insights

Mitotane treatment of adrenocortical carcinoma cells alters mitochondria-associated membranes (MAMs), reducing ubiquinone (Q10) and recruiting GRIPAP1 protein, potentially mediating cell death.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Oncology

Background:

  • Mitotane inhibits SOAT1 and induces cell death in adrenocortical carcinoma (ACC).
  • Adrenal cortex cells are prone to ferroptosis, a cell death pathway involving ACSL4.
  • SOAT1 and ACSL4 localize to mitochondria-associated membranes (MAMs).

Purpose of the Study:

  • To investigate the role of MAMs in mitotane-induced adrenocortical cell death.
  • To analyze protein and lipid changes within MAMs upon mitotane treatment.

Main Methods:

  • Isolation of MAMs from NCI-H295S cells treated with mitotane or RSL3 (ferroptosis inducer).
  • Western blotting for quality control of MAM fractions.
  • Lipid and protein mass spectrometry to identify molecular changes.

Main Results:

  • MAM fractions were enriched in SOAT1 and FATE1, and contained ACSL4.
  • Mitotane treatment reduced ubiquinone (Q10) and heme B within MAMs.
  • GRIPAP1 protein was uniquely identified in MAMs of mitotane-treated cells and its expression was upregulated.

Conclusions:

  • Locally reduced Q10 in MAMs may impair respiratory chain activity and increase free radicals, contributing to mitotane's effects.
  • GRIPAP1 recruitment to MAMs might be involved in transducing mitotane-induced cell death signals.